You are here: Industry Insights > Lenalidomide

News List

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China PharmaSources.com
December 20, 2022
InnoCare Pharma announced today that the Company has received approval from the Center for Drug Evaluation (CDE) to conduct a single-arm, open-label, multi-cohort phase II clinical trial.
Four-drug combo therapy shows benefit for newly-diagnosed myeloma patients pharmatimes
July 27, 2021
A four-drug combination therapy has shown significant benefit for patients with newly diagnosed myeloma, according to a new analysis led by researchers from The Institute of Cancer Research, London (ICR).
NICE recommends Kyprolis triple combination treatment for multiple myeloma pharmatimes
March 22, 2021
The National Institute for Health and Care Excellence (NICE) has recommended a triple combination therapy comprised of Amgen’s Kyprolis, lenalidomide and dexamethasone for the treatment of previously-treated multiple myeloma patients.
Lenalidomide recommended for use with rituximab by NICE europeanpharmaceuticalreview
March 03, 2020
NICE has given its positive opinion to lenalidomide in combination with rituximab as a ‘chemotherapy-free’ treatment for lymphoma.
FDA Approves Lenalidomide for Follicular and Marginal Zone Lymphoma americanpharmaceuticalreview
May 30, 2019
On May 28, 2019, the Food and Drug Administration (FDA) approved lenalidomide (REVLIMID®, Celgene) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma drugs
May 29, 2019
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma.
Top 10 Small Molecule Drugs: A Half were Oncology Drugs PharmaSources/Yuntian
April 24, 2019
Small molecule drugs still have a huge share in the global market at present, and are the biggest source of drugs.
Chinese authorities approve Sino Pharma’s lenalidomide for multiple melanoma pharmaceutical-technology
January 21, 2019
Chinese Sino Pharmaceutical has announced that China’s Revlimid has approved its subsidiary Chia-Tai Tianqing Pharmaceutical’s anti-tumour drug lenalidomide for multiple melanoma....